Sterilizing activity of novel TMC207- and PA-824-containing regim

Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis. Antimicrob Agents Chemother. 2011;55:5485–92.PubMedCentralPubMedCrossRef 38. Shang S, Shanley CA, Caraway ML, et al. Activities of TMC207, rifampin, and pyrazinamide against Mycobacterium tuberculosis buy I-BET151 infection in guinea pigs. Antimicrob Agents Chemother. 2011;55:124–31.PubMedCentralPubMedCrossRef 39. Andries K, Gevers T, Lounis N. Bactericidal potencies of new regimens are not predictive of their sterilizing potencies in a murine model of tuberculosis. Antimicrob Agents Chemother.

2010;54:4540–4.PubMedCentralPubMedCrossRef 40. Veziris N, Ibrahim M, Lounis N, et al. A once-weekly R207910-containing regimen exceeds activity of the standard daily regimen in murine tuberculosis. Am J Respir Crit Care Med. 2009;179:75–9.PubMedCrossRef 41. Ibrahim M, Truffot-Pernot C, Andries K, Jarlier V, Veziris N. Sterilizing activity of R207910 (TMC207)-containing regimens

in the murine model of tuberculosis. Am J Respir Crit Care Med. 2009;180:553–7.PubMedCrossRef 42. Lenaerts AJ, Hoff D, Aly S, et al. Location of persisting mycobacteria in a Guinea pig model of tuberculosis revealed by r207910. Antimicrob Agents Chemother. 2007;51:3338–45.PubMedCentralPubMedCrossRef 43. Lounis SB202190 nmr N, Veziris N, Chauffour A, Truffot-Pernot C, Andries K, Jarlier V. Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration. Antimicrob Agents Chemother. 2006;50:3543–7.PubMedCentralPubMedCrossRef 44. Upadhayaya RS, Lahore SV, Sayyed

AY, Dixit SS, Shinde PD, Chattopadhyaya J. Conformationally-constrained indeno[2,1-c]quinolines—a new class of anti-mycobacterial agents. Org Biomol Chem. 2010;8:2180–97.PubMedCrossRef 45. Reddy VM, Einck L, Andries K, Nacy CA. In vitro interactions between new antitubercular drug candidates SQ109 and TMC207. Antimicrob Agents Chemother. 2010;54:2840–6.PubMedCentralPubMedCrossRef 46. Diacon AH, Maritz JS, Venter A, et al. Time to detection of the growth of Mycobacterium tuberculosis in MGIT 960 for determining the early bactericidal activity Abiraterone mw of antituberculosis agents. Eur J Clin Selleckchem PLX 4720 Microbiol Infect Dis. 2010;29:1561–5.PubMedCrossRef 47. Dhillon J, Andries K, Phillips PP, Mitchison DA. Bactericidal activity of the diarylquinoline TMC207 against Mycobacterium tuberculosis outside and within cells. Tuberculosis. 2010;90:301–5.PubMedCrossRef 48. Ji B, Lefrancois S, Robert J, Chauffour A, Truffot C, Jarlier V. In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans. Antimicrob Agents Chemother. 2006;50:1921–6.PubMedCentralPubMedCrossRef 49. Sala C, Dhar N, Hartkoorn RC, et al. Simple model for testing drugs against nonreplicating Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2010;54:4150–8.PubMedCentralPubMedCrossRef 50.

Related posts:

1. J Bacteriol
   
   2006,188(6):2290–2293 PubMedCrossRef 17 Mars
2. Appl Environ Microbiol 1997, 63:2421–2431 PubMedCentralPubMed 29
3. 41 Guimarães CA, Linden R: Programmed cell death: apoptosis and
4. Nature 2002, 417:552–555 PubMedCrossRef
   
   18 Cole GT, Hala
5. Periodontol 2006, 42:80–87 CrossRef 8 Zijnge V, Ammann T, Thurnh